Literature DB >> 19669841

Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.

Kentaroh Yamamoto1, Hiroshi Imamura, Yutaka Matsuyama, Kiyoshi Hasegawa, Yoshifumi Beck, Yasuhiko Sugawara, Masatoshi Makuuchi, Norihiro Kokudo.   

Abstract

BACKGROUND: Alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) are well-known tumor markers of hepatocellular carcinoma (HCC). The aims of this study are to calculate the sensitivity/specificity of AFP and DCP measurement for the diagnosis of HCC, measure response rates of the markers following curative-intent resections, determine the correlations between the marker levels and clinicopathological prognostic variables, and determine the correlations between the marker levels before hepatectomy and those at diagnosis of recurrence.
METHODS: A retrospective cohort study of 714 consecutive patients with HCC undergoing hepatectomy was carried out.
RESULTS: The areas under the receiver operating characteristic curves were 0.79 versus 0.91 for AFP and DCP, respectively (P < 0.001). Positive AFP and DCP status became negative at 6 months post surgery in 184/229 (80.3%) and 245/246 (99.6%) patients, respectively (cutoff values being 20 ng/ml for AFP and 40 mAU/ml for DCP; P < 0.0001). No correlation was found between marker levels (rs = 0.23). The level of DCP, but not that of AFP, showed a close correlation with tumor size (rs = 0.51 and 0.19, respectively). They were associated with indices of tumor invasiveness without showing any specific associations. AFP and DCP levels in patients showing recurrence in </=6 months correlated with the levels measured before surgery (rs = 0.78 and 0.49, respectively) but not in those showing recurrence after 2 years (rs = 0.31 and 0.30, respectively).
CONCLUSIONS: DCP is a more accurate, albeit complementary, HCC marker than AFP. While the levels of both markers increased with advancing tumor growth, no specific associations were found. The marker values at recurrence indicated the type of recurrence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19669841     DOI: 10.1245/s10434-009-0618-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  47 in total

1.  Differential effects of vitamin K1 on AFP and DCP levels in patients with unresectable HCC and in HCC cell lines.

Authors:  Brian I Carr; Ziqiu Wang; Meifung Wang; Gang Wei
Journal:  Dig Dis Sci       Date:  2010-12-28       Impact factor: 3.199

2.  The postresection alpha-fetoprotein in cirrhotic patients with hepatocellular carcinoma. An independent predictor of outcome.

Authors:  Marc-Antoine Allard; Antonio Sa Cunha; Aldrick Ruiz; Eric Vibert; Mylène Sebagh; Denis Castaing; René Adam
Journal:  J Gastrointest Surg       Date:  2014-01-09       Impact factor: 3.452

3.  AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC.

Authors:  Kentaroh Yamamoto; Hiroshi Imamura; Yutaka Matsuyama; Yukio Kume; Hitoshi Ikeda; Gary L Norman; Zakera Shums; Taku Aoki; Kiyoshi Hasegawa; Yoshifumi Beck; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  J Gastroenterol       Date:  2010-07-13       Impact factor: 7.527

Review 4.  Significant biomarkers for the management of hepatocellular carcinoma.

Authors:  Yasuteru Kondo; Osamu Kimura; Tooru Shimosegawa
Journal:  Clin J Gastroenterol       Date:  2015-04-09

5.  Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.

Authors:  Atsushi Nanashima; Naota Taura; Takafumi Abo; Tatsuki Ichikawa; Ichiro Sakamoto; Takeshi Nagayasu; Kazuhiko Nakao
Journal:  Dig Dis Sci       Date:  2011-06-25       Impact factor: 3.199

6.  Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma.

Authors:  Xin-Sen Xu; Kai Qu; Chang Liu; Yue-Lang Zhang; Jun Liu; Yan-Zhou Song; Peng Zhang; Si-Nan Liu; Hu-Lin Chang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

7.  Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization.

Authors:  Takuma Arai; Akira Kobayashi; Ayumi Ohya; Masaaki Takahashi; Takahide Yokoyama; Akira Shimizu; Hiroaki Motoyama; Norihiko Furusawa; Tsuyoshi Notake; Noriyuki Kitagawa; Hiroshi Sakai; Hiroshi Imamura; Masumi Kadoya; Shin-Ichi Miyagawa
Journal:  Int J Clin Oncol       Date:  2013-11-12       Impact factor: 3.402

8.  Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment.

Authors:  Wei Yang; Kun Yan; S Nahum Goldberg; Muneeb Ahmed; Jung-Chieh Lee; Wei Wu; Zhong-Yi Zhang; Song Wang; Min-Hua Chen
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

9.  Liver transplantation for small hepatocellular carcinoma.

Authors:  Naoko Kamo; Toshimi Kaido; Shintaro Yagi; Hideaki Okajima; Shinji Uemoto
Journal:  Hepatobiliary Surg Nutr       Date:  2016-10       Impact factor: 7.293

10.  Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma.

Authors:  Shuzhe Yao; Jianping Zhang; Haiyan Chen; Yan Sheng; Xiaoying Zhang; Zhiyan Liu; Cuijuan Zhang
Journal:  J Histochem Cytochem       Date:  2013-05-16       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.